Statin-fibrate combination for mixed dyslipidaemia: a limited option?

References

• Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-33
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Karagiannis A, et al. Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets 2009;10:320-7
   PubMed Web of Science ®Google Scholar
• Chait A, Brazg RL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-6
   PubMed Web of Science ®Google Scholar
• Austin MA, Breslow JL, Hennekens CH, et al. Low density lipoprotein subclass patters and risk of myocardial infarction. JAMA 1988;260:1917-21
   PubMed Web of Science ®Google Scholar
• Tornvall P, Båvenholm P, Landou C, et al. Relation of plasma levels of apoprotein B-containing lipoproteins angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993;88:2180-9
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H. Identification of individuals at high risk for myocardial infarction. Atherosclerosis 1994;110(Suppl.):11S-21S
   Google Scholar
• Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk 1995;2:197-205
   PubMedGoogle Scholar
• Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin–gemfibrozil combination therapy. JAMA 1990;264:71-5
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin–fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003;19:155-68
   PubMed Web of Science ®Google Scholar
• Kontopoulos AG, Athyros VG, Papageorgiou AA, et al. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis 1996;7:843-50
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin–fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997;80:608-13
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Kontopoulos AG. Statin–fibrate combinations in patients with combined hyperlipidemia. Atherosclerosis 2001;155:263-4
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin versus four statin–fibrate combinations in patients with familial combined hyperlipidaemia. J Cardiovasc Risk 2002;9:33-9
   PubMedGoogle Scholar
• Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-202
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005;54:1065-74
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Morrell J, Hemsley D, et al. The effect of fibrate–statin combination therapy on cardiovascular events: a retrospective cohort analysis. Curr Med Res Opinion 2010;13:2141-46
   Google Scholar
• Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009;151:622-30
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks FM, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes Vasc Dis Res 2008;5:319-35
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
   PubMed Web of Science ®Google Scholar
• Simes J, Voysey M, O’Connell R, et al. FIELD Study Investigators. A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PLoS One 2010;5:e8580
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
   Google Scholar
• Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45
   PubMed Web of Science ®Google Scholar
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Collins D, Horvath KV, et al. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 2008;57:77-83
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8
   PubMed Web of Science ®Google Scholar
• Papadakis JA, Ganotakis ES, Jagroop IA, et al. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999;69:237-44
   PubMed Web of Science ®Google Scholar